Phase II study of the safety and efficacy of temsirolimus in east asian patients with advanced renal cell carcinoma

Yan Sun, Sun Rha, Se Hoon Lee, Jun Guo, Takeshi Ueda, Shukui Qin, Seiji Naito, Maria Cincotta, Kota Tokushige, Hideyuki Akaza

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Objective: Temsirolimus, an inhibitor of the mammalian target of rapamycin, is approved for treatment of patients with advanced renal cell carcinoma in the USA and Europe. Temsirolimus was not yet evaluated in East Asian patients. Methods: This non-randomized Phase II study enrolled 82 patients with advanced renal cell carcinoma [20 (24%) Japanese, 30 (37%) Korean and 32 (39%) Chinese patients; median age (range): 55 (26-83) years]. Most (71%) received prior systemic therapy for metastatic disease; two-thirds were intermediate risk. Six Japanese patients received intravenous temsirolimus 20 mg/m. 2 weekly for tolerability assessment (Group A); the remaining 76 received a 25 mg flat dose weekly (Group B). Temsirolimus was dosed once weekly. Primary efficacy end point was the Response Evaluation Criteria in Solid Tumors-defined clinical benefit rate in the intent-to-treat population. Results: In the entire population, regardless of treatment group, the clinical benefit rate was 48% (95% confidence interval: 36, 59). Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4). No patient in Group A demonstrated dose-limiting toxicity. The most frequent Grade 3 or 4 drug-related adverse events were anemia, hyperglycemia, hypophosphatemia and stomatitis (5% each). Serious adverse events reported in ≥5% of patients were pneumonia (9%) and interstitial lung disease (7%). Temsirolimus and its major metabolite, sirolimus, were long-lived throughout the dosage interval, with no evidence of accumulation. Conclusion: Temsirolimus was well tolerated and showed promising activity in Japanese, Korean and Chinese patients with advanced renal cell carcinoma.

Original languageEnglish
Article numberhys110
Pages (from-to)836-844
Number of pages9
JournalJapanese Journal of Clinical Oncology
Issue number9
Publication statusPublished - 2012 Sept

Bibliographical note

Funding Information:
We thank all of the patients and their families, research nurses, study coordinators and operations staff who participated in this study. We also thank Christine H. Blood, PhD, of Peloton Advantage, LLC, for assistance with manuscript preparation, which was funded by Pfizer.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Phase II study of the safety and efficacy of temsirolimus in east asian patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this